Candel Therapeutics Inc (CADL) - Total Liabilities
Based on the latest financial reports, Candel Therapeutics Inc (CADL) has total liabilities worth $13.47 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore CADL operating cash flow to assess how effectively this company generates cash.
Candel Therapeutics Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Candel Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check Candel Therapeutics Inc (CADL) asset resilience to evaluate the company's liquid asset resilience ratio.
Candel Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Candel Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fujian Jinsen Forestry Co Ltd
SHE:002679
|
China | CN¥1.21 Billion |
|
Gospell Digital Technology Co Ltd
SHE:002848
|
China | CN¥321.64 Million |
|
Tsogo Sun
JSE:TSG
|
South Africa | ZAC9.74 Billion |
|
Vigil Neuroscience Inc
NASDAQ:VIGL
|
USA | $45.44 Million |
|
E. W. Scripps Co Class A
NASDAQ:SSP
|
USA | $3.76 Billion |
|
GEM Services Inc
TW:6525
|
Taiwan | NT$2.13 Billion |
|
EVN Finance JSC
VN:EVF
|
Vietnam | ₫73.18 Trillion |
Liability Composition Analysis (2019–2024)
This chart breaks down Candel Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CADL company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Candel Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Candel Therapeutics Inc (2019–2024)
The table below shows the annual total liabilities of Candel Therapeutics Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $40.54 Million | +42.46% |
| 2023-12-31 | $28.46 Million | -7.63% |
| 2022-12-31 | $30.80 Million | +22.89% |
| 2021-12-31 | $25.07 Million | -59.47% |
| 2020-12-31 | $61.84 Million | +14.66% |
| 2019-12-31 | $53.94 Million | -- |
About Candel Therapeutics Inc
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developin… Read more